The Caring Ambassadors Program provides this website to help you and your loved ones understand your disease
and some of the healthcare option available to you.
Our three main methods to fight lung cancer are to Empower patients and providers with access to free educational materials, and resources; to Educate communities about the importance of screening and to share current information with patients and their families; and to Advocate for access to screening and treatment for lung cancer for all communities. Knowledge empowers you to ask the necessary questions to become your own best advocate. When your questions have been asked and answered, you and your healthcare providers will be in the best possible situation to determine the best treatment approach for you.
Caring Ambassadors is seeking focus group participantsHave you or a loved one been diagnosed
with lung cancer? Your opinion is valuable to us.
You may be eligible for a paid focus group opportunity.
Caring Ambassadors has released Lung Cancer Choices 3rd Edition, an amazing resource for those diagnosed with lung cancer.
Are you a Caregiver?
Caregiver Choices, a resource for all those who find themselves in the role of caregiver for someone who has been diagnosed with lung cancer.
Treatment Advancements in NSCLC Change Therapy Recommendations in 2019 NCCN Guidelines
“Due to an active research landscape, the National Comprehensive Cancer Network (NCCN) Guidelines for non–small cell lung cancer (NSCLC) have had 3 recent updates that include numerous clinically relevant recommendations.1”
Ramucirumab/Erlotinib Combo Improves PFS in Frontline EGFR+ NSCLC
“The combination of ramucirumab (Cyramza) and erlotinib (Tarceva) significantly improved progression-free survival (PFS) compared with placebo and erlotinib as a frontline treatment for patients with metastatic EGFR-mutant non–small cell lung cancer (NSCLC), meeting the primary endpoint of the RELAY trial (NCT02411448).1”
Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC
“Immunotherapy has dramatically improved the outlook for select patients with metastatic non–small cell lung cancer (NSCLC), but its reach could extend even further when combined with other approaches, said Naiyer A. Rizvi, MD.”
New Developments in Neoadjuvant Therapy for Lung Cancer
“Lung cancer is the leading cause of cancer death in the United States and worldwide. While most patients present with advanced metastatic disease for which a cure is elusive, increased use of spiral CT screening has led to identification of more early-stage patients who can be treated.”
Blood Tumor Mutational Burden Could Identify Benefit from Checkpoint Inhibitors in NSCLC
“Blood tumor mutational burden – which measures the quantity of mutations found in a tumor – may be a potential biomarker in identifying which patients with non-small cell lung cancer (NSCLC) could benefit from anti-PD-1 and anti-PD-L1 therapy, according to results published in JAMA Oncology.”
Can exercise prevent lung cancer?
“Researchers undertook this prospective study to assess the associations between cardiorespiratory fitness and the incidence of lung cancer and lung cancer mortality in men.”
Study finds AI could reduce false positives in lung cancer screening
“A study by a research team in the US has found that artificial intelligence (AI) technology could substantially cut false positives while screening for lung cancer.”